Amgen Inc. (AMGN)
312.80
-2.24 (-0.71%)
At close: Mar 21, 2025, 3:03 PM
-0.71% (1D)
Bid | 312.72 |
Market Cap | 168.04B |
Revenue (ttm) | 33.22B |
Net Income (ttm) | 4.06B |
EPS (ttm) | 7.56 |
PE Ratio (ttm) | 41.38 |
Forward PE | 13.46 |
Analyst | Hold |
Ask | 312.8 |
Volume | 2,418,411 |
Avg. Volume (20D) | 3,007,759 |
Open | 311.82 |
Previous Close | 315.04 |
Day's Range | 311.24 - 314.11 |
52-Week Range | 253.30 - 346.85 |
Beta | 0.52 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopaus...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 17, 1983
Employees 28,000
Stock Exchange NASDAQ
Ticker Symbol AMGN
Website https://www.amgen.com
Analyst Forecast
According to 22 analyst ratings, the average rating for AMGN stock is "Hold." The 12-month stock price forecast is $324, which is an increase of 3.58% from the latest price.
Stock ForecastsNext Earnings Release
Amgen Inc. is scheduled to release its earnings on May 1, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.5%
Amgen shares are trading higher after the company ...
Unlock content with
Pro Subscription
1 month ago
+0.05%
Amgen shares are trading lower. The company reported Q4 financial results.